Enzalutamide for treating hormone-sensitive metastatic prostate cancer

2.1 Enzalutamide (Xtandi, Astellas) is indicated for 'the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price of a 112‑capsule pack of 40 mg enzalutamide is £2,734.67 (excluding VAT; BNF online, accessed May 2020). The daily dose of enzalutamide is 160 mg and costs £97.67.

2.4 The company has a commercial arrangement. This makes enzalutamide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.